What Experts Predicts About Antisense and RNAi Therapeutics Market Growth
The global antisense
and RNAi therapeutics market is expected to grow at a CAGR of 8.67%
during the forecast period. Major challenges hindering the growth of the global
antisense and RNAi therapeutics market include high price of RNAi drugs,
difficulty faced in the delivery of treatment, and toxic side effects. As per the latest market research report published by
Technavio, the antisense and RNAi therapeutics market size will grow USD 1.45
billion during 2019-2023. Get the free sample report below for the detailed
information.
Most of the RNAi therapeutics are meant to be
administered by parenteral routes. After the administration, the targeted
delivery at a particular gene or a gene sequence becomes a major hurdle.
If RNAi therapy needs to be administered across the
blood-brain barrier for a disease such as Huntington’s disease, its delivery to
the brain cannot be accomplished through a simple injection or a pill. The
patient compliance in the delivery method developed by Ionis Pharmaceuticals
remains undefined.
OBLIMERSEN, an antisense molecule, was a promising
approach to the treatment of a variety of cancers but was rejected due to
challenges associated with its delivery. Such challenges need to be addressed
through various innovative delivery approaches so that the emergence of these
novel therapies not hindered.
However, despite the challenges, the global antisense
and RNAi therapeutics market is expected to grow in an accelerating momentum
during the forecast period. To know the complete and in-depth analysis and
forecast of this market get the complete report by clicking the link below.
Get the Complete Report @ http://bit.ly/35l4yHh
Comments
Post a Comment